A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

NCT06297629 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Abandoned

Conditions

Allogeneic Stem Cell Transplantation

Interventions

DRUG: ASTX727
DRUG: Donor Lymphocyte Infusion

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]